Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH

被引:21
作者
Israeli, O
Gotlieb, WH
Friedman, E
Goldman, B
Ben-Baruch, G
Aviram-Goldring, A
Rienstein, S [1 ]
机构
[1] Chaim Sheba Med Ctr, Danek Gertner Inst Human Genet, IL-52621 Tel Hashomer, Ramat Gan, Israel
[2] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, Ramat Gan, Israel
[3] Chaim Sheba Med Ctr, Dept Gynecol Oncol, Ramat Gan, Israel
关键词
D O I
10.1016/S0090-8258(03)00375-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Our purpose was to get an overview of the genetic events leading to the development of familial and sporadic ovarian tumors and to identify chromosomal regions that may contain genes important in tumor progression. Methods. The comparative genomic hybridization (CGH) technique was employed in a total of 46 epithelial ovarian or peritoneal tumors: 27 sporadic tumors, 11 tumors disected from BRCA1 mutation (185delAG) carriers, and eight from BRCA2 mutation (6174delT) carriers (familial tumors). Results. The average number of genetic alterations (deletions and amplifications) was significantly (alpha = 0.0069) higher in familial tumors (9.17 +/- 4.25 alterations per tumor in the BRCA1 mutation carriers and 7.25 +/- 6.06 in the BRCA2 mutation carriers) compared to the sporadic group (4.26 +/- 3.61 alterations per tumor). The pattern of the chromosome amplifications resembled in the three groups and the most common amplifications detected were at chromosomes 8q, 3q, and 2q. The pattern of the chromosomal deletions varied between the groups. Among the BRCA1 group, the most common deletions were in chromosomes 9 and 19. The BRCA2 group showed a lower frequency of deletions. Deletion of chromosome 16 and 22 were the most frequent ones. No specific chromosomal deletion was significantly indicated in the sporadic group. Conclusions. Familial ovarian tumors exhibit a significantly higher number of chromosomal aberrations and genomic imbalances and nonrandom genetic changes were characterized in the BRCA1 and BRCA2 groups. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:629 / 636
页数:8
相关论文
共 49 条
[1]  
Abeliovich D, 1997, AM J HUM GENET, V60, P505
[2]  
Berchuck A, 1998, CLIN CANCER RES, V4, P2433
[3]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[4]  
BRYNDORF T, 1995, AM J HUM GENET, V57, P1211
[5]   Comparative genomic hybridization analysis of nonfunctioning pituitary tumors [J].
Daniely, M ;
Aviram, A ;
Adams, EF ;
Buchfelder, M ;
Barkai, G ;
Fahlbusch, R ;
Goldman, B ;
Friedman, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1801-1805
[6]   Rig is a novel Ras-related protein and potential neural tumor suppressor [J].
Ellis, CA ;
Vos, MD ;
Howell, H ;
Vallecorsa, T ;
Fults, DW ;
Clark, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :9876-9881
[7]   DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones [J].
Fiegler, H ;
Carr, P ;
Douglas, EJ ;
Burford, DC ;
Hunt, S ;
Smith, J ;
Vetrie, D ;
Gorman, P ;
Tomlinson, IPM ;
Carter, NP .
GENES CHROMOSOMES & CANCER, 2003, 36 (04) :361-374
[8]   Genotype-phenotype correlation in hereditary multiple exostoses [J].
Francannet, C ;
Cohen-Tanugi, A ;
Le Merrer, M ;
Munnich, A ;
Bonaventure, J ;
Legeai-Mallet, L .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (07) :430-434
[9]   Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:: Analysis of 10,000 individuals [J].
Frank, TS ;
Deffenbaugh, AM ;
Reid, JE ;
Hulick, M ;
Ward, BE ;
Lingenfelter, B ;
Gumpper, KL ;
Scholl, T ;
Tavtigian, SV ;
Pruss, DR ;
Critchfield, GC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1480-1490
[10]  
Gajewski W, 1998, Surg Oncol Clin N Am, V7, P317